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Psoriatic arthritis
AbstrAct
Objective to evaluate the efficacy and safety of 
ixekizumab alone or with concomitant conventional 
disease-modifying antirheumatic drugs (cDMarDs) versus 
placebo in patients with active psoriatic arthritis (Psa) as 
part of a SPirit-P1 subgroup analysis (nct01695239).
Methods Patients were stratified by cDMarD use 
(concomitant cDMarDs use (including methotrexate) 
or none (past or naïve use)) and randomly assigned to 
treatment groups (ixekizumab 80 mg every 4 weeks 
(iXeQ4W) or every 2 weeks (iXeQ2W) or placebo). efficacy 
was evaluated versus placebo at week 24 by the american 
college of rheumatology criteria (acr20/50/70), modified 
total Sharp score and Health assessment Questionnaire-
Disability index (HaQ-Di). Safety was assessed according 
to cDMarD status.
Results regardless of concomitant cDMarD usage, 
acr20, acr50 and acr70 response rates were 
significantly higher versus placebo with iXeQ4W and 
iXeQ2W. the proportion of patients achieving HaQ-Di 
minimal clinically important difference was significantly 
higher versus placebo with iXeQ4W with concomitant 
cDMarD use and iXeQ2W, regardless of concomitant 
cDMarD use. treatment-emergent adverse events (ae) 
were more frequent versus placebo for either ixekizumab-
dosing regimen, regardless of concomitant cDMarD use. 
Serious aes were not higher versus placebo, regardless of 
concomitant cDMarD use.
Conclusion ixekizumab treatment improved measures 
of disease activity and physical function in patients with 
active Psa relative to placebo, when used with or without 
concomitant cDMarD therapy.
InTROduCTIOn
Psoriatic arthritis (PsA) is a chronic inflam-
matory arthritis that is often associated 
with psoriasis and other extra-articular 
manifestations including joint inflammation 
(peripheral and/or axial) and structural joint 
damage.1 Quality of life in patients with PsA 
is poor and worse than the quality of life in 
Key messages
What is already known about this subject?
 ► Patients with psoriatic arthritis are clinically 
managed with biologic agents and concomitant 
conventional disease-modifying antirheumatic 
drugs (cDMarDs).
 ► limited evidence exists demonstrating the 
efficacy of biologic agents when used alone or 
with concomitant cDMarDs, and there is limited 
treatment guidance currently available regarding 
the use of combination therapy.
What does this study add?
 ► this subset analysis of SPirit-P1 demonstrated 
that ixekizumab, a high-affinity monoclonal 
antibody that selectively targets interleukin (il)-
17a, improved measures of disease activity and 
physical function in patients with active psoriatic 
arthritis at 24 weeks relative to placebo, regardless 
of concomitant cDMarD use.
How might this impact on clinical practice?
 ► the findings from this study offer clinicians 
additional insights on the utility of employing an 
anti-il-17a targeting agent, as represented by 
ixekizumab, either alone or with concomitant 
cDMarD use, including methotrexate, in biologic-
naïve patients with active psoriatic arthritis.
 ► the evidence provided herein has clinical relevance 
as the therapeutic options for the treatment of 
psoriatic arthritis continue to expand and treatment 
guidelines evolve.
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patients with psoriasis alone.2 Abundant evidence indi-
cates that the proinflammatory cytokine interleukin (IL)-
17A promotes joint inflammation and damage in PsA.1 
Ixekizumab is a high-affinity monoclonal antibody that 
selectively targets IL-17A and has been demonstrated to 
improve PsA disease activity and physical function, and 
inhibit structural progression of joint damage in biolog-
ic-naïve patients with active PsA.3 4 
Treatment of patients with PsA with biologics with 
concomitant conventional disease-modifying antirheu-
matic drugs (cDMARDs) is common, but no specific 
recommendations have been released by the Group 
for Research and Assessment of Psoriasis and Psoriatic 
Arthritis (GRAPPA) due to insufficient evidence.5 Prior 
studies of tumour necrosis factor inhibitors (TNFi)6–14 
and an IL-17A inhibitor15 16 indicate that clinical efficacy 
is achieved with biologics alone or biologics with concom-
itant methotrexate (MTX), a commonly used cDMARD. 
In addition, PsA registry studies report minimal or no 
additional improvement in patients with PsA who have 
been treated with TNFis and concomitant cDMARDs 
versus TNFis alone.17–20 In the SPIRIT-P1 study, 64% of 
patients used cDMARDs at baseline.3 Here, we evaluated 
the efficacy and safety of ixekizumab relative to placebo 
when used alone or with concomitant cDMARDs during 
the double-blind treatment period of the SPIRIT-P1 
study.
MaTeRIals and MeTHOds
study design
We analysed efficacy, physical function and safety data 
from the 24-week double-blind, active and placebo-con-
trolled period of the SPIRIT-P1 trial of ixekizumab.3 At 
study initiation, patients were randomised, and received 
either ixekizumab 80 mg every 4 weeks (IXEQ4W), ixeki-
zumab 80 mg every 2 weeks (IXEQ2W), adalimumab 
40 mg every 2 weeks (ADA) or placebo, all administered 
subcutaneously. ADA was the active reference arm, but 
ADA results were not included in this report.3 In ixeki-
zumab treatment groups, patients received an initial 
160 mg dose of ixekizumab. Patients were stratified by 
cDMARD usage (current use (must have been treated for 
at least 12 weeks prior to baseline and on a stable dosage 
for at least 8 weeks), past use (no current cDMARD 
use, with past use occurring more than 8 weeks prior 
to study baseline) or naïve to cDMARDs (no past use of 
cDMARDs)) prior to randomisation. Patients who were 
taking concomitant medications, including cDMARDs, 
were required to remain on the same background treat-
ment regimen, unless required to stop, modify or change 
concomitant medication for safety reasons, through the 
24-week double-blind treatment period, or if they were 
designated an inadequate responder and required rescue 
therapy at week 16.
Participants
Enrolled patients were biologic-naïve and fulfilled the 
Classification Criteria for Psoriatic Arthritis21; had ≥3 
of 68 tender joints and ≥3 of 66 swollen joints; had 
either ≥1 PsA-related hand or foot erosion on centrally 
read X-rays or C reactive protein >6 mg/L; and active 
or documented personal history of plaque psoriasis. All 
patients provided written informed consent. The study 
was registered as SPIRIT-P1 on  ClinicalTrials. gov 
(NCT01695239).
efficacy, physical function and safety assessments
PsA disease activity was measured by the proportion of 
patients achieving the American College of Rheumatology 
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Figure 1 ACR response rates at 24 weeks in patients 
treated with PBO, IXEQ4W or IXEQ2W alone or in 
combination with cDMARDs or MTX. The proportions of 
patients achieving ACR20 (A), ACR50 (B) and ACR70 (C) 
are shown. The study was not designed to test equivalence 
or non-inferiority of treatment with ixekizumab alone 
versus treatment with ixekizumab in combination with 
cDMARDs. ACR20/50/70, 20%/50%/70% American College 
of Rheumatology response; cDMARD, conventional disease-
modifying antirheumatic drugs; PBO, placebo; IXEQ4W, 
80 mg ixekizumab once every 4 weeks; IXEQ2W, 80 mg 
ixekizumab once every 2 weeks; n, number of patients; MTX, 
methotrexate. *P<0.05, **P<0.01, ***P<0.001, all versus PBO.
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(ACR) 20, ACR50 and ACR70 responses at week 2422; 
change from baseline in van der Heijde modified total 
Sharp score (mTSS) at week 2423; change from base-
line in the Health Assessment Questionnaire-Disability 
Index (HAQ-DI) at week 24; and also by calculation of 
the proportion of patients achieving minimal clinically 
important difference (MCID) in the HAQ-DI.24 25 Safety 
was assessed by the proportion of patients experiencing 
treatment-emergent adverse events (TEAE), serious 
adverse events (AE) and discontinuations due to AE.
statistical analyses
Efficacy analyses were conducted on the intent-to-treat 
population, defined as all randomly assigned patients 
and on subgroups defined by concomitant cDMARD 
(MTX, ciclosporin, leflunomide or sulfasalazine) or 
MTX usage. Analysis subgroups were defined as those 
receiving ixekizumab with concomitant cDMARDs, ixeki-
zumab with concomitant MTX or ixekizumab alone 
(either cDMARD-naïve or past use). Subgroup analyses of 
ACR20 response rate and mTSS assessments in patients 
subdivided by concomitant cDMARD use were prespeci-
fied analyses, while all other analyses presented here were 
post-hoc analyses. Safety analyses were conducted on 
the safety population, defined as all randomly assigned 
patients who received at least one dose of study medi-
cation, and grouped by the defined analysis subgroups. 
Treatment by subgroup interaction was tested at the 
significance level of 0.10 using either a logistic regression 
model for categorical data or an analysis of covariance 
(ANCOVA) model for continuous data, as appropriate. 
Within each subgroup, Fisher’s exact test was used for 
treatment comparisons of categorical endpoints and AE 
data, and an ANCOVA model was used for comparisons 
of mTSS and HAQ-DI data. All comparisons were rela-
tive to the placebo group. Missing values were imputed 
by non-responder imputation for categorical endpoints, 
linear extrapolation for mTSS change from baseline and 
last observation carried forward for HAQ-DI data.
ResulTs
The SPIRIT-P1 patient population was previously 
described by Mease and colleagues.3 In the patient popu-
lation treated with concomitant cDMARDs at baseline, 
Table 2 Structural disease progression at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in 
combination with cDMARD or MTX
Concomitant
treatment
cDMARD MTX
None
(cDMARD-naïve or past use at 
baseline)
PBO, 
n=58
IXEQ4W, 
n=63
IXEQ2W, 
n=60
PBO, 
n=48
IXEQ4W, 
n=52
IXEQ2W, 
n=49
PBO,
 n=35
IXEQ4W, 
n=37
IXEQ2W, 
n=37
mTSS LSM 
change from 
baseline at 
week 24 (SE)
0.44
(0.100)
0.11
(0.096)*
0.11
(0.098)*
0.52
(0.135)
0.13
(0.121)*
0.14
(0.114)*
0.57
(0.157)
0.25
(0.153)
0.03
(0.153)*
The study was not designed to test equivalence or non-inferiority of treatment with ixekizumab alone versus treatment with 
ixekizumab with concomitant cDMARDs.
*P<0.05 versus PBO.
cDMARD, conventional disease-modifying antirheumatic drugs; IXEQ2W, 80 mg ixekizumab once every 2 weeks; IXEQ4W, 
80 mg ixekizumab once every 4 weeks; LSM, least squares mean; mTSS, van der Heijde modified total Sharp score; MTX, 
methotrexate; n, number of patients; PBO, placebo.
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Figure 2 HAQ-DI change from baseline and proportion of 
patients achieving MCID after 24 weeks in patients treated 
with PBO, IXEQ4W or IXEQ2W alone or in combination 
with cDMARDs or MTX. (A) LSM changes from baseline of 
HAQ-DI. (B) Proportion of patients achieving MCID. The 
study was not designed to test equivalence or non-inferiority 
of ixekizumab alone versus treatment with ixekizumab 
in combination with cDMARDs. cDMARD, conventional 
disease-modifying antirheumatic drugs; HAQ-DI, Health 
Assessment Questionnaire-Disability Index; IXEQ2W, 80 mg 
ixekizumab once every 2 weeks; IXEQ4W, 80 mg ixekizumab 
once every 4 weeks; LSM, least squares mean; MCID, 
minimal clinically important difference; MTX, methotrexate; 
n, number of patients; PBO, placebo. *P<0.05, **P<0.01, 
***P<0.001, all versus PBO.
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83.8%–85.5% of patients were treated with MTX. Patient 
demographics and characteristics were similar across 
subgroups (table 1).
No interaction in treatment-by-cDMARD use was 
observed in the study (P>0.1). Patients treated with either 
IXEQ4W or IXEQ2W had significantly higher ACR20, 
ACR50 and ACR70 response rates at 24 weeks compared 
with placebo, regardless of concomitant cDMARD use 
(figure 1A–C). IXEQ4W with concomitant MTX use had 
significantly higher ACR20 response rates and numeri-
cally higher, but not statistically significant, ACR50 and 
ACR70 response rates relative to placebo (figure 1). ACR 
response rates for IXEQ2W with concomitant MTX use 
were consistent with those reported relative to placebo 
for IXEQ2W with concomitant cDMARD use.
Progression of structural damage, as measured by 
change from baseline in mTSS at 24 weeks, was signifi-
cantly less in patients treated with IXEQ4W or IXEQ2W 
with concomitant cDMARD or MTX use and IXEQ2W 
alone when compared with the placebo groups (table 2). 
In patients treated with IXEQ4W alone, change from 
baseline in mTSS at 24 weeks was numerically lower than 
placebo (0.25 vs 0.57, respectively), but not statistically 
significant.
Improvements in physical function, as assessed by 
HAQ-DI, showed that patients treated with either 
IXEQ4W or IXEQ2W had significantly greater improve-
ment than placebo regardless of concomitant cDMARD 
or MTX use (figure 2A). The proportion of patients who 
reached a HAQ-DI MCID (improvement in HAQ-DI 
total score ≥0.35 from baseline) was significantly higher 
than placebo for IXEQ4W alone and IXEQ2W, regard-
less of concomitant cDMARD or MTX use (figure 2B). 
Although not statistically significant, treatment with 
IXEQ4W with concomitant cDMARDs or MTX use had a 
numerically higher proportion of patients who achieved 
HAQ-DI MCID relative to placebo.
Overall, a numerically higher proportion of patients 
who received IXEQ4W or IXEQ2W experienced at 
least one TEAE when compared with patients receiving 
placebo, regardless of concomitant cDMARD or MTX use 
(table 3). In the groups with significantly higher frequen-
cies of TEAEs reported, injection site reactions were the 
most frequently reported TEAEs (IXEQ4W+cDMARD: 
11.8%, n=8; IXEQ2W+cDMARD: 12.7%, n=8), but this is 
consistent with previous SPIRIT-P1 reports for the overall 
treatment groups.3 Mild TEAEs were significantly higher 
versus placebo for IXEQ4W with concomitant cDMARD 
or MTX use. The incidence of moderate TEAEs, severe 
TEAEs, serious TEAEs and TEAEs leading to discontin-
uation was similar versus placebo across all treatment 
groups, regardless of concomitant cDMARD or MTX use.
dIsCussIOn
In biologic-naïve patients with PsA, ixekizumab demon-
strated efficacy relative to placebo, regardless of concom-
itant cDMARD use. Improvements were observed rela-
tive to placebo in disease activity, inhibition of structural 
progression of disease and physical function in patients 
treated with ixekizumab, regardless of concomitant 
cDMARD use. Furthermore, the overall safety profile was 
consistent with previous ixekizumab reports in patients 
with psoriasis and PsA across treatment subgroups.3 26 27
Reports from PsA randomised controlled trials (RCTs) 
for TNFis6–14 and an IL-17A inhibitor15 16 support our 
results. All of these studies, including our results from 
patients treated with ixekizumab, indicate clinical effi-
cacy with biologics relative to placebo, regardless of 
concomitant cDMARD use. In addition, results directly 
comparing the efficacy of biologics alone with biologics 
with concomitant cDMARD use are available from anal-
yses of PsA registries, which also support the results we 
observed in patients treated with ixekizumab. Studies of 
Table 3 Safety overview after 24 weeks according to concomitant cDMARD or MTX use at baseline, subdivided by treatment
Concomitant 
treatment cDMARD MTX
None (cDMARD-naïve or past 
use at baseline)
PBO, 
n=69
IXEQ4W, 
n=68
IXEQ2W, 
n=63
PBO, 
n=59
IXEQ4W, 
n=57
IXEQ2W, 
n=53
PBO, 
n=37
IXEQ4W, 
n=39
IXEQ2W, 
n=39
Treatment-emergent 
AE, n (%)
30 (43.5) 42 (61.8)* 40 (63.5)* 27 (45.8) 36 (63.2) 34 (64.2) 20 (54.1) 29 (74.4) 27 (69.2)
  Mild 15 (21.7) 28 (41.2)* 23 (36.5) 13 (22.0) 25 (43.9)* 18 (34.0) 12 (32.4) 15 (38.5) 18 (46.2)
  Moderate 13 (18.8) 13 (19.1) 14 (22.2) 12 (20.3) 10 (17.5) 13 (24.5) 8 (21.6) 11 (28.2) 7 (17.9)
  Severe 2 (2.9) 1 (1.5) 3 (4.8) 2 (3.4) 1 (1.8) 3 (5.7) 0 3 (7.7) 2 (5.1)
Serious AE, n (%) 2 (2.9) 3 (4.4) 4 (6.3) 1 (1.7) 2 (3.5) 0 0 3 (7.7) 3 (7.7)
AE leading to 
discontinuation, n (%)
2 (2.9) 1 (1.5) 4 (7.5) 2 (3.4) 1 (1.8) 4 (7.5) 0 1 (2.6) 0
The study was not designed to test equivalence or non-inferiority of treatment with ixekizumab alone versus treatment with ixekizumab 
combined with cDMARDs.
*P<0.05 versus PBO.
AE, adverse events; cDMARD, conventional disease-modifying antirheumatic drugs; IXEQ2W, 80 mg ixekizumab once every 2 weeks; 
IXEQ4W, 80 mg ixekizumab once every 4 weeks; MTX, methotrexate; n, number of patients; PBO, placebo.
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the Danish biologics registry (DANBIO), which contained 
764 patients with PsA, found that clinical improvements, 
as reflected by ACR20 responses, were associated with 
biologic treatment with concomitant MTX use, but not 
for other outcome measures, including ACR50 and 
ACR70.18 Furthermore, analyses of the Norwegian longi-
tudinal observational study on disease-modifying anti-
rheumatic drugs (NOR-DMARD), which contained 440 
patients with PsA, observed no significant difference in 
clinical outcomes with and without concomitant MTX 
use for ACR20, ACR50 and ACR70 responses.17
The findings of this study, with support from other 
RCTs, indicate that ixekizumab and other biologics are 
clinically effective in PsA, regardless of concomitant 
cDMARD or MTX use through 24 weeks of treatment. 
The European League Against Rheumatism (EULAR) 
recommendations include the use of TNFis with concom-
itant cDMARDs, but EULAR was unable to recommend 
IL-12/23 and IL-17 inhibitor use with concomitant 
cDMARDs due to a lack of published evidence.28 In 
contrast, GRAPPA noted in their 2015 treatment 
recommendations that based on available study results, 
concomitant therapy does not yield additional improve-
ments beyond those achieved with biologics alone.5 
Acknowledging these guidelines, we note that this study 
did not compare the efficacy of using an IL-17A antag-
onist alone with use with concomitant cDMARDs, but 
instead provides clinicians with additional insights on the 
utility of using an IL-17A antagonist, as represented by 
ixekizumab, either alone or with concomitant cDMARDs, 
including MTX, in biologic-naïve patients with active PsA.
These results suggest that efficacy is achieved with ixeki-
zumab relative to placebo when given with or without 
concomitant cDMARDs, but it has limitations. First, these 
data are subset analyses of the SPIRIT-P1 trial, which was 
designed to compare treatments with the placebo group 
alone; thus patients were not randomised to receive or 
not receive concomitant cDMARDs.3 In addition, the 
stratification of patients by cDMARD status at baseline 
balanced these characteristics across treatment arms, but 
did not ensure balance of these characteristics within 
treatment arms. Hence, this study design does not allow 
for making robust comparisons between patients treated 
with and without concomitant cDMARDs. Despite these 
limitations, abundant evidence exists from RCTs6–13 15 16 
for other PsA biologic therapies indicating that efficacy 
is achieved with or without concomitant cDMARD use. 
These studies are in alignment with our findings that 
ixekizumab is effective relative to placebo in PsA, regard-
less of cDMARD use. In addition, due to the short-term 
nature of the period in this study, the impact of concom-
itant therapy on long-term outcomes and duration of 
response was not investigated. Such an investigation 
would be informative but would need to be undertaken 
as part of a long-term registry study or RCT.
In summary, ixekizumab effectively reduced the 
severity of PsA symptoms, inhibited structural damage 
and improved physical function in patients relative to 
placebo, regardless of concomitant cDMARD use. The 
safety profile of ixekizumab with or without concomi-
tant cDMARD use is consistent with previous reports in 
patients with PsA and psoriasis.3 26 27
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